공시 • May 29
KOREA PHARMA Co., Ltd. announced that it has received KRW 15 billion in funding On May 28, 2026, KOREA PHARMA Co., Ltd. closed the transaction. 공시 • May 22
KOREA PHARMA Co., Ltd. announced that it expects to receive KRW 15 billion in funding KOREA PHARMA Co., Ltd. has announced a private placement of Series 5 Unregistered Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 15,000,000,000 on May 20, 2026. The transaction includes participation from The Time-M Private Equity Trust advised by Samsung Securities Co., Ltd for KRW 2,000,000,000, NH Absolute Return General Private Investment Trust No. 1 advised by Samsung Securities Co., Ltd for KRW 2,000,000,000, NH-Orion Mezzanine New Technology Fund No. 1 for KRW 1,500,000,000 and NH Fine Value No. 1 New Technology Fund for KRW 1,000,000,000 and others.The Bonds are 100% convertible into 1,391,207 common shares of the company at a conversion price value of KRW 10,782 and carry interest rate of 0% and maturity interest rate of 0%. The conversion billing period starts from May 28, 2027 to April 28, 2031. The transaction has been approved by the board of directors of the company. The Bonds have a maturity date of May 28, 2031. The transaction is expected to close on May 28, 2026.The transaction is subject to 1 year hold period. 공시 • Mar 13
KOREA PHARMA Co., Ltd., Annual General Meeting, Mar 27, 2026 KOREA PHARMA Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: seminar room, 317, seja-ro, gyeonggi-do, hwaseong South Korea Upcoming Dividend • Dec 22
Upcoming dividend of ₩50.00 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 28 April 2026. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (0.8%). Board Change • Nov 11
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Outside Director Euna Lee was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Nov 07
KOREA PHARMA Co., Ltd. announces Annual dividend, payable on April 28, 2026 KOREA PHARMA Co., Ltd. announced Annual dividend of KRW 50.0000 per share payable on April 28, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. New Risk • Nov 04
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩143.3b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 21% per year over the past 5 years. High level of non-cash earnings (30% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (1.7% net profit margin). Market cap is less than US$100m (₩143.3b market cap, or US$99.6m). New Risk • Aug 28
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 30% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 21% per year over the past 5 years. High level of non-cash earnings (30% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (1.7% net profit margin). New Risk • Apr 08
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩147.1b (US$99.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩147.1b market cap, or US$99.3m). 공시 • Mar 13
KOREA PHARMA Co., Ltd., Annual General Meeting, Mar 28, 2025 KOREA PHARMA Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: seminar room, 317, seja-ro, jeongnam-myeon, gyeonggi-do, hwaseong South Korea Upcoming Dividend • Dec 20
Upcoming dividend of ₩50.00 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 28 April 2025. Trailing yield: 0.3%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.1%). Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩15,960, the stock trades at a trailing P/E ratio of 58x. Average trailing P/E is 12x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 69% over the past three years. Valuation Update With 7 Day Price Move • Nov 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩18,620, the stock trades at a trailing P/E ratio of 67.8x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 66% over the past three years. Valuation Update With 7 Day Price Move • Oct 16
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to ₩20,950, the stock trades at a trailing P/E ratio of 76.3x. Average trailing P/E is 16x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 62% over the past three years. 공시 • May 30
Korea Pharma Co., Ltd Submits A New Drug Application to the Korean Ministry of Food and Drug Safety for the Review and Approval of Accrufer to Treat Patients with Iron Deficiency Anaemia in Korea Shield Therapeutics plc announced that its Accrufer partner for Korea, Korea Pharma Co., Ltd. (Korea Pharma) has submitted a New Drug Application (NDA) to the Korean Ministry of Food and Drug Safety (MFDS) for the review and approval of Accrufer to treat patients with iron deficiency anaemia in Korea. Pending a successful review, approval of Accrufer in Korea is anticipated in 2025. Korea Pharma's MFDS filing follows the successful completion of a pharmacokinetic (PK) study in Korea. The PK study confirms that the absorption of iron from Accrufer is comparable between patients in Korea and the patient population enrolled in the key clinical studies supporting Accrufer® effectiveness and safety. Reported Earnings • May 19
First quarter 2024 earnings released: EPS: ₩121 (vs ₩7.00 in 1Q 2023) First quarter 2024 results: EPS: ₩121 (up from ₩7.00 in 1Q 2023). Revenue: ₩20.3b (flat on 1Q 2023). Net income: ₩1.32b (up ₩1.24b from 1Q 2023). Profit margin: 6.5% (up from 0.4% in 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance. Upcoming Dividend • Dec 20
Inaugural dividend of ₩50.00 per share Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 29 April 2024. This is the first dividend for KOREA PHARMA since going public. The average dividend yield among industry peers is 1.1%. New Risk • Dec 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. New Risk • Oct 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Upcoming Dividend • Dec 21
Inaugural dividend of ₩50.00 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 28 April 2023. This is the first dividend for KOREA PHARMA since going public. The average dividend yield among industry peers is 1.0%. Reported Earnings • Nov 16
Third quarter 2022 earnings released: EPS: ₩59.00 (vs ₩135 in 3Q 2021) Third quarter 2022 results: EPS: ₩59.00 (down from ₩135 in 3Q 2021). Revenue: ₩20.4b (up 6.0% from 3Q 2021). Net income: ₩648.4m (down 56% from 3Q 2021). Profit margin: 3.2% (down from 7.6% in 3Q 2021). The decrease in margin was driven by higher expenses. Reported Earnings • Nov 13
Third quarter 2022 earnings released: EPS: ₩59.00 (vs ₩135 in 3Q 2021) Third quarter 2022 results: EPS: ₩59.00 (down from ₩135 in 3Q 2021). Revenue: ₩20.4b (up 6.0% from 3Q 2021). Net income: ₩648.4m (down 56% from 3Q 2021). Profit margin: 3.2% (down from 7.6% in 3Q 2021). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improved over the past week After last week's 15% share price gain to ₩26,100, the stock trades at a trailing P/E ratio of 65.1x. Average trailing P/E is 19x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 54% over the past year. Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment improved over the past week After last week's 32% share price gain to ₩33,500, the stock trades at a trailing P/E ratio of 60.5x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 39% over the past year. Valuation Update With 7 Day Price Move • Jun 29
Investor sentiment improved over the past week After last week's 15% share price gain to ₩23,850, the stock trades at a trailing P/E ratio of 43.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 53% over the past year. Buying Opportunity • Jun 23
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 49%. The fair value is estimated to be ₩26,188, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last year. Earnings per share has grown by 63%. Valuation Update With 7 Day Price Move • Jun 14
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩25,900, the stock trades at a trailing P/E ratio of 46.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 42% over the past year. Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩38,000, the stock trades at a forward P/E ratio of 70x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 46% over the past year. Upcoming Dividend • Dec 22
Inaugural dividend of ₩50.00 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 28 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for KOREA PHARMA since going public. The average dividend yield among industry peers is 0.8%. Is New 90 Day High Low • Jan 13
New 90-day high: ₩31,950 The company is up 1.0% from its price of ₩31,700 on 15 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period. Is New 90 Day High Low • Dec 09
New 90-day low: ₩20,200 The company is down 24% from its price of ₩26,750 on 10 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period.